CompletedNCT03488784
Natural History of Limb Girdle Muscular Dystrophy Type 2A and Type 2E
Studying Beta-sarcoglycan-related limb-girdle muscular dystrophy R4
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Lindsay Alfano
- Principal Investigator
- Linda Lowes, PT PhDNationwide Children's Hospital
- Enrollment
- 100 enrolled
- Eligibility
- All sexes
- Timeline
- 2016 – 2025
Study locations (1)
- Nationwide Children's Hospital, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03488784 on ClinicalTrials.govOther trials for Beta-sarcoglycan-related limb-girdle muscular dystrophy R4
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06246513A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4Sarepta Therapeutics, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05876780A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)Sarepta Therapeutics, Inc.
See all trials for Beta-sarcoglycan-related limb-girdle muscular dystrophy R4 →